A Phase 2 clinical trial on how LSD can be used to treat cluster headaches is underway in Switzerland. The trial is being conducted at Liechti Lab at University Hospital Basel. Patients willing to participate in this study were recruited in January this year and the trial is now underway.
Cluster headaches are also referred to as “suicide headaches” since the pain they cause is so severe that many patients with this condition develop suicidal tendencies during an episode. Cluster headaches have also been variously described as the most painful condition that anyone can ever suffer from.
The pain caused by cluster headaches usually manifests above an eye or on one side of a person’s head, and this pain can last anywhere from a few weeks to several months. This makes cluster headaches one of the most significant causes of lost productivity since a person is unable to function normally when the condition strikes.
Anecdotal and non-clinical reports suggest that LSD can abort an attack of cluster headaches, or even decrease their intensity and frequency. This possibility is an exciting one for the medical community because the current medications available for managing cluster headaches don’t do a good job of giving sufferers relief. If LSD can help, the way cluster headaches are treated could be flipped on its head.
To this end, the Phase 2 clinical trial being conducted in Switzerland is aimed at evaluating how LSD can be administered orally in three doses given over a three-week period in order to manage cluster headaches. The study is randomized, double-blind and placebo-controlled so that the findings can pass the scrutiny done by the scientific community and regulators in different jurisdictions.
Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”), the company collaborating with the Swiss researchers, plans to use this trial to gather evidence about the possibility of conducting future FDA-approved drug trials. If the research provides results that encourage further study, the potential treatment could qualify for Orphan Drug classification by the FDA, and this would open the door to some drug development incentives from the FDA.
The Swiss lab and MindMed are therefore keen to learn what specific LSD administration modalities target cluster headaches and deliver lasting relief to patients. Needless to say, MindMed will have exclusive global rights to the data and any patents accruing from the findings of this ongoing study. But, the biggest winners will be the patients who, for the first time, will have a treatment option that addresses their condition in a meaningful way.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.